CLDX Celldex Therapeutics (CLDX) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · In vitro & in vivo diagnostic substances · CIK 0000744218
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
154
13F, latest reported quarter
Celldex Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Celldex Therapeutics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 4 earlier Form 4 trades (code P or S) here by this insider (1 buy, 3 sales), the last on Aug 13, 2025.
- The trade is 13.5% of the 30,796 shares held after it.
- 1 other insider sold within 30 days.
- 154 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP & GENERAL COUNSEL Jimenez Freddy A. sold about $121.2K of CLDX on Dec 4, 2025; 1 other insider sold within 30 days and 154 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Jun 3, 2024.
- The trade is 236.6% of the 20,833 shares held after it.
- 1 other insider sold within 30 days.
- 154 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Wright Richard M. sold about $1.2M of CLDX on Nov 13, 2025, the largest insider sale at the company since 2024; 1 other insider sold within 30 days and 154 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (1 buy, 1 sale), the last on Jun 3, 2024.
- The trade is 1.0% of the 35,392 shares held after it.
- No other insider sold within 30 days.
- 154 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP & GENERAL COUNSEL Jimenez Freddy A. sold about $8.2K of CLDX on Aug 13, 2025, the largest insider sale at the company since 2024; 154 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (1 buy, 1 sale), the last on Jun 3, 2024.
- The trade is 1.2% of the 34,962 shares held after it.
- No other insider sold within 30 days.
- 154 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP & GENERAL COUNSEL Jimenez Freddy A. sold about $10.9K of CLDX on Aug 13, 2025, the largest insider sale at the company since 2024; 154 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Aug 15, 2022.
- The trade is 28.5% of the 40,284 shares held after it.
- No other insider bought within 30 days.
- 154 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRESIDENT & CEO Marucci Anthony S bought about $308.4K of CLDX on Nov 11, 2024, the largest insider purchase at the company on our record; 154 funds added in the latest 13F quarter.44 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
154 funds bought in last quarter
more than 83% of Pharma & Biotech
Revenue
-78.0% year over year
below 87% of Pharma & Biotech
Margin
-16748.0% net margin
the lowest in Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
15.1% of the float short (float per yahoo 2026-10-26) · 3.8 days to cover · settled 2026-09-30
more than 83% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch CLDX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+9.5%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CLDX: institutional holders (13F)
13F holdings, latest reported quarter
9,543,671 sh
$355.1M
7,002,530 sh
$260.6M
5,322,908 sh
$198.1M
3,900,427 sh
$145.1M
3,722,888 sh
$138.5M
Congress trades in CLDX
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CLDX planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
CLDX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Simplify Propel Opportunities ETF
$2.0M position · as of 2026-06-30
2.6%
Eventide Healthcare & Life Sciences Fund
$38.6M position · as of 2026-06-30
2.2%
ALPS Medical Breakthroughs ETF
$2.2M position · as of 2026-05-31
1.3%
AlphaCentric Life Sciences and Healthcare Fund
$475.7K position · as of 2026-06-30
1.0%
DWS Small Cap Growth Fund
$3.1M position · as of 2026-06-30
1.0%
Fidelity Advisor Biotechnology Fund
$19.5M position · as of 2026-07-31
0.9%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
18 registered trials, 7 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
8
Phase 1
1 active
6
Phase 2
2 active
4
Phase 3
4 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Anthony S. Marucci.
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$8.4M
$3.7M
$3.1M
+1678%
+59%
2022
$5.4M
$10.1M
$2.1M
+1899%
+53%
2021
$6.0M
$13.9M
$2.4M
+1633%
+37%
2020
$3.0M
$6.4M
$1.3M
+686%
+11%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 154 funds added last quarter. Each figure is a federal filing, dated the day it went public.
CLDX financials
Revenue growth
-78.0%
XBRL, annual
Net margin
-16748.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$158.0K
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM CLDX
| FY Dec 2025 | $1.5M |
| FY Dec 2024 | $7.0M |
| FY Dec 2023 | $6.9M |
| FY Dec 2022 | $2.4M |
| FY Dec 2021 | $4.7M |
| Jun 2026 | $22.0K |
| Mar 2026 | $15.0K |
| Dec 2025 | $121.0K |
| Sep 2025 | $0 |
| Jun 2025 | $730.0K |
| Mar 2025 | $695.0K |
| Dec 2024 | $1.2M |
| Sep 2024 | $3.2M |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM CLDX
| FY Dec 2025 | -16,737% |
| FY Dec 2024 | -2,249% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | -7,753% |
| Mar 2025 | -7,740% |
| Dec 2024 | -4,008% |
| Sep 2024 | -1,320% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$242.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM CLDX
| FY Dec 2025 | -$213.7M |
| FY Dec 2024 | -$159.7M |
| FY Dec 2023 | -$109.1M |
| FY Dec 2022 | -$105.6M |
| FY Dec 2021 | -$62.2M |
| Jun 2026 | -$60.6M |
| Mar 2026 | -$67.2M |
| Dec 2025 | -$65.2M |
| Sep 2025 | -$49.1M |
| Jun 2025 | -$44.7M |
| Mar 2025 | -$54.6M |
| Dec 2024 | -$33.2M |
| Sep 2024 | -$55.9M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity CLDX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt CLDX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-43.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity CLDX
| FY Dec 2025 | -40.6% |
| FY Dec 2024 | -26.8% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -43.9% |
| Mar 2026 | -48.9% |
| Dec 2025 | -40.6% |
| Sep 2025 | -32.4% |
| Jun 2025 | -27.2% |
| Mar 2025 | -23.2% |
| Dec 2024 | -26.8% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-40.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CLDX
| FY Dec 2025 | -37.6% |
| FY Dec 2024 | -25.1% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -40.8% |
| Mar 2026 | -45.4% |
| Dec 2025 | -37.6% |
| Sep 2025 | -30.5% |
| Jun 2025 | -26.0% |
| Mar 2025 | -22.2% |
| Dec 2024 | -25.1% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital CLDX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-47.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed CLDX
| FY Dec 2025 | -44.7% |
| FY Dec 2024 | -32.9% |
| FY Dec 2023 | -40.2% |
| FY Dec 2022 | -30.2% |
| FY Dec 2021 | -21.9% |
| Jun 2026 | -47.2% |
| Mar 2026 | -53.0% |
| Dec 2025 | -44.7% |
| Sep 2025 | -36.8% |
| Jun 2025 | -31.8% |
| Mar 2025 | -28.0% |
| Dec 2024 | -32.9% |
| Sep 2024 | -35.8% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing CLDX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value CLDX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-10.5%
TTM free cash flow over market value at close 2026-10-23
FCF yield CLDX
| FY Dec 2025 | -11.8% |
| FY Dec 2024 | -9.5% |
| FY Dec 2023 | -5.8% |
| FY Dec 2022 | -5.0% |
| FY Dec 2021 | -3.4% |
| Jun 2026 | -8.3% |
| Mar 2026 | -10.7% |
| Dec 2025 | -11.8% |
| Sep 2025 | -10.6% |
| Jun 2025 | -14.0% |
| Mar 2025 | -14.4% |
| Dec 2024 | -9.5% |
| Sep 2024 | -7.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing CLDX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $1.5M | $7.0M | $6.9M | $2.4M |
| Operating income | -$287.4M | -$195.1M | -$154.5M | -$115.2M |
| Net income | -$258.8M | -$157.9M | -$141.4M | -$112.3M |
| EPS (diluted) | -3.90 | -2.45 | -2.92 | -2.40 |
| Operating cash flow | -$210.9M | -$157.8M | -$107.3M | -$103.7M |
| Cash | $28.9M | $28.4M | $34.8M | $29.4M |
SEC XBRL, fiscal years, as known on 2026-10-27
CLDX Stock Sonar score 4/7 axes
Find similar shapesCompareCLDX ranks highest on institutional and government (68th percentile) and profitability (54th), and lowest on growth (13th), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
